Should You Buy, Sell or Hold Hikma Pharmaceuticals Plc And London Stock Exchange Group Plc After Today’s News?

Roland Head assesses the latest news from Hikma Pharmaceuticals Plc (LON:HIK) and London Stock Exchange Group Plc (LON:LSE).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in FTSE 250 pharmaceutical group Hikma Pharmaceuticals (LSE: HIK) dropped 5% in early trade this morning after the group said that a sharp fall in sales of a generic gout treatment had dented profits.

Diluted earnings

However, the market seems to have warmed to Hikma’s results as the day has progressed. At the time of writing, the shares are modestly higher. So was it good news or bad for this highly-rated stock?

Hikma’s total sales were down 3% while core operating profit was down 4%, to $409m. Post-tax profits were down by 9% to $252m, but the dividend was held unchanged at 32 cents for the full year.

This leaves Hikma stock trading on a trailing P/E of 18 and a trailing yield of 1.3%. On the face of it this is not especially cheap. However, the outlook for Hikma is dominated by the recent $2.1bn acquisition of Roxane, which is expected to add around $600m to revenue in 2016.

Market confidence in this deal was shaken in February when Hikma announced a $535m reduction in the price it would pay for Roxane. The revised deal was triggered by Hikma’s first sight of Roxane’s 2015 financial results. These showed that Roxane’s 2015 profits were likely to be slightly lower than in 2014.

Although Roxane is expected to add significantly to Hikma’s revenue in 2016, the firm now estimates that the acquisition “will be slightly dilutive to adjusted earnings per share in 2016”. What this means is that additional profits from Roxane will not be enough to offset the dilutive effect of the new shares which were issued in part-payment for Roxane.

This situation is expected to reverse in 2017, when Hikma expects earnings per share growth as a result of the Roxane deal. However, it does highlight the risk involved in major acquisitions. Hikma trades on a 2016 forecast P/E of about 18. This is probably reasonable, but I’d rather know more about Roxane’s contribution before deciding whether to buy.

A waiting game

The London Stock Exchange Group (LSE: LSE) published the long-awaited details of an all-share merger with Frankfurt stock exchange owner Deutsche Börse this morning.

The deal would give existing LSE shareholders a 45.6% share of the combined group, with existing Deutsche shareholders owning the remainder. Today’s statement claims that ongoing cost savings of €450m could be achieved, which would reduce the group’s combined operating costs of €2,200m by nearly 20%.

A second benefit would be that many big investors would also benefit from having to provide lower levels of collateral to the exchanges. This is because their open positions on the two exchanges would offset each other to some extent. This would reduce the level of margin payments that would be required.

However, the LSE-Deutsche Börse deal may not proceed. US Group Intercontinental Exchange (ICE) has already indicated its interest in making an offer. Analysts expect that such a deal might include a cash element, which could be more appealing to LSE shareholders.

Today’s deal seems sound enough to me, but an ICE offer could be more generous. If I was a London Stock Exchange shareholder, I would hold on and wait for further news.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »